Skip to main content

Table 1 Baseline clinicopathological parameters of included patients

From: Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma

  Paired (N = 83) Metastatic (N = 80) P value
Age, n (%)    0.546
 < 70 76 (91.6) 71 (88.8)  
 ≥ 70 7 (8.4) 9 (11.2)  
Gender, n (%)    0.873
 Male 54 (65.1) 53 (66.3)  
 Female 29 (34.9) 27 (33.7)  
ISUP, n (%)    0.066
 < 4 49 (67.1) 58 (80.6)  
 ≥ 4 24 (32.9) 14 (19.4)  
Histological Type, n (%)    0.032
 ccRCC 59 (71.1) 68 (61.3)  
 Non-ccRCC 24 (28.9) 12 (38.7)  
Pathology, n (%)
 Sarcomatoid 6 (19.4) 2 (28.6) 0.509
 Necrosis 25 (80.6) 5 (71.4) 0.491
Nephrectomy, n (%)    0.001
 Yes 80 (96.4) 57 (77.0)  
 No 3 (3.6) 17 (23.0)  
ECOG, n (%)    0.801
 0–1 53 (70.7) 59 (76.6)  
 ≥ 2 22 (29.3) 18 (23.4)  
IMDC, n (%)    0.293
 Low 14 (18.3) 19 (28.4)  
 Intermediate 43 (57.3) 37 (55.2)  
 High 18 (24.0) 11 (16.4)  
T stage, n (%)    0.587
 < 2b 46 (59.7) 12 (66.7)  
 ≥ 2b 31 (40.3) 6 (33.3)  
Metastasis, n (%)
 Lung 6 (8.1) 17 (28.8) 0.010
 Brain 7 (9.5) 12 (20.3) 0.192
 Liver 1 (1.4) 2 (3.4) 0.539
 Bone 18 (24.3) 22 (37.3) 0.389
 Lymph node 42 (56.8) 6 (10.2) 0.001
Treatment, n (%)
 Cytokine 14 (16.9) 8 (10.0) 0.345
 Target therapy 34 (41.0) 30 (37.5) 0.882
 Radiotherapy 7 (8.4) 7 (8.8) 0.673
 Chemotherapy 3 (3.6) 5 (6.2) 0.360
Unknown 25 (30.1) 30 (37.5)